"Best New Biotech Development Programme" - OBN Award Winner Announced
6 October 2014
At the OBN Awards dinner at the Ashmolean Museum in Oxford on 2 October 2014 Adaptimmune won the "Best New Biotech Development Programme" award which was sponsored by J A Kemp. Adaptimmune uses unique genetic engineering technology to create T-cell receptors which target specific cancer cells. In June this year, Adaptimmune announced a strategic collaboration and licensing agreement with GlaxoSmithKline.
Main news page